Cancer vaccine development: on the way to break immune tolerance to malignant cells
- 28 July 2004
- journal article
- review article
- Published by Elsevier in Experimental Cell Research
- Vol. 299 (2) , 267-278
- https://doi.org/10.1016/j.yexcr.2004.06.017
Abstract
No abstract availableKeywords
This publication has 163 references indexed in Scilit:
- CD8+ T cells, NK cells and IFN-γ are important for control of tumor with downregulated MHC class I expression by DNA vaccinationGene Therapy, 2003
- Quantitating cellular immune responses to cancer vaccinesSeminars in Oncology, 2003
- CD22 as a target of passive immunotherapySeminars in Oncology, 2003
- A Single-nucleotide Deletion Leads to Rapid Degradation ofTAP-1 mRNA in a Melanoma Cell LineJournal of Biological Chemistry, 2003
- Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumorsCancer Gene Therapy, 2003
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Kinetics of cytokine expression in melanoma metastases classifies immune responsivenessInternational Journal of Cancer, 2001
- Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cellsCancer Gene Therapy, 2000
- Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administrationCancer Gene Therapy, 2000
- Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastasesCancer, 1999